Stockreport

Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

Galera Therapeutics, Inc.  (GRTX) 
PDF Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the randomized, double [Read more]